Most Read Articles
Rachel Soon, 03 Apr 2019

The Malaysian Community Pharmacy Guild (MCPG) has submitted a seven-point proposal for comprehensively including community pharmacists (CPs) in the national healthcare system.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

E6201 shows potential in treatment of advanced solid malignancies

12 Jun 2018

A phase I study of E6201 has shown the feasibility and safety of an intermittent regimen of 320 mg/m2 by intravenous (IV) infusion once-weekly (qw) for the first 3 weeks of a 28-day cycle in patients with advanced solid malignancies, including melanoma.

“Additionally, we show preliminary evidence of clinical efficacy, confirming the potential of MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase) inhibition and selective MEK1 inhibition, as a therapeutic strategy in cancer,” the investigators said.

In part A of the study (dose escalation), sequential cohorts received E6201 IV over 30 min qw (days [D]1 + 8 + 15 of a 28-day cycle), starting at 20 mg/m2, increasing to 720 mg/m2 or the maximum tolerated dose (MTD). In part B (expansion), patients with B-type Raf (BRAF)-mutated or wild-type (WT) melanoma received E6201 320 mg/m2 IV over 60 minutes qw (D1 + 8 + 15 of a 28-day cycle) or 160 mg/m2 IV twice-weekly (D1 + 8 + 15 + 18 of a 28-day cycle; BRAF-mutated only).

MTD was 320 mg/m2 qw in part A (n=25) and confirmed in part B (n=30). QT prolongation (n=4) and eye disorders (n=3) were some of the reported adverse events.

There was a dose-related exposure of E6201, with pharmacokinetics characterized by extensive distribution and fast elimination. Partial response was reported in one patient during part A (BRAF-mutated papillary thyroid cancer; 480 mg/m2 qw) and in three during part B (2 BRAF-mutated melanoma; 1 BRAF-WT melanoma; all receiving 320 mg/m2 qw).

“E6201 is being further investigated in a phase I/II trial in patients with advanced haematologic malignancies with the FLT3 mutation,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 03 Apr 2019

The Malaysian Community Pharmacy Guild (MCPG) has submitted a seven-point proposal for comprehensively including community pharmacists (CPs) in the national healthcare system.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.